

# Hypertension in pregnancy

Quality standard

Published: 16 July 2013

[www.nice.org.uk/guidance/qs35](http://www.nice.org.uk/guidance/qs35)

# Contents

Introduction .....	5
Why this quality standard is needed .....	5
How this quality standard supports delivery of outcome frameworks .....	6
Coordinated services.....	9
List of quality statements .....	10
Quality statement 1: Pre-pregnancy advice for women with treated hypertension.....	12
Quality statement.....	12
Rationale .....	12
Quality measures .....	12
What the quality statement means for different audiences.....	13
Source guidance.....	13
Definitions of terms used in this quality statement .....	13
Equality and diversity considerations.....	14
Quality statement 2: Antenatal assessment of pre-eclampsia risk.....	16
Quality statement.....	16
Rationale .....	16
Quality measures .....	16
What the quality statement means for different audiences .....	17
Source guidance.....	18
Definitions of terms used in this quality statement .....	18
Quality statement 3: Antenatal blood pressure targets.....	21
Quality statement.....	21
Rationale .....	21
Quality measures .....	21
What the quality statement means for different audiences.....	21
Source guidance.....	22
Quality statement 4: Assessing women with severe hypertension in pregnancy .....	23

---

Quality statement.....	23
Rationale .....	23
Quality measures .....	23
What the quality statement means for different audiences.....	24
Source guidance.....	24
Definitions of terms used in this quality statement .....	24
<b>Quality statement 5: Admission to hospital for women with pre-eclampsia .....</b>	<b>26</b>
Quality statement.....	26
Rationale .....	26
Quality measures .....	26
What the quality statement means for different audiences.....	27
Source guidance.....	27
Definitions of terms used in this quality statement .....	28
<b>Quality statement 6: Timing of birth for women with pre-eclampsia .....</b>	<b>30</b>
Quality statement.....	30
Rationale .....	30
Quality measures .....	30
What the quality statement means for different audiences.....	31
Source guidance.....	31
Definitions of terms used in this quality statement .....	32
<b>Quality statement 7: Transfer of information about ongoing management .....</b>	<b>34</b>
Quality statement.....	34
Rationale .....	34
Quality measures .....	34
What the quality statement means for different audiences.....	35
Source guidance.....	35
Definitions of terms used in this quality statement .....	35
<b>Quality statement 8: Communicating information about future risks.....</b>	<b>37</b>

Quality statement.....	37
Rationale .....	37
Quality measures .....	37
What the quality statement means for different audiences.....	38
Source guidance.....	38
Definitions of terms used in this quality statement .....	38
Equality and diversity considerations.....	40
Using the quality standard.....	41
Quality measures .....	41
Levels of achievement .....	41
Using other national guidance and policy documents.....	41
Diversity, equality and language .....	42
Development sources.....	43
Evidence sources.....	43
Policy context .....	43
Definitions and data sources for the quality measures .....	43
Related NICE quality standards .....	44
Topic Expert Group and NICE project team .....	45
Topic Expert Group.....	45
NICE project team .....	46
Update information.....	47
About this quality standard.....	48

This standard is based on CG62 and NG133.

This standard should be read in conjunction with QS22, QS28, QS32, QS3, QS37, QS15, QS46, QS60, QS105, QS135 and QS192.

## Introduction

This quality standard covers pre-pregnancy advice for women with pre-existing hypertension, as well as the antenatal, intrapartum and postnatal care of women at risk of or with hypertensive disorders of pregnancy. For more information, see the [scope](#) for this quality standard.

## Why this quality standard is needed

Hypertension in pregnancy can occur for several reasons. Women might have pre-existing hypertension when they become pregnant. This includes women with hypertension at the booking appointment or before 20 weeks of pregnancy. New-onset hypertension (presenting after 20 weeks of pregnancy) is known as gestational hypertension. It can occur in isolation, or in association with proteinuria when it is known as pre-eclampsia. Pre-eclampsia is a multisystem disorder that can affect almost all maternal organ systems and the unborn baby. Women with either pre-existing hypertension or gestational hypertension are at increased risk of developing pre-eclampsia.

Hypertensive disorders in pregnancy carry risks for both the mother and the baby. They can result in substantial maternal morbidity and place women at an increased lifetime risk of cardiovascular disease. Reports on maternal and perinatal deaths show that 5% of stillbirths without congenital abnormality occurred in infants whose mothers had pre-eclampsia. Hypertension in pregnancy is associated with 8–10% of all preterm births and more than half of women with severe pre-eclampsia give birth preterm. Most children born of pregnancies affected by preterm pre-eclampsia will have restricted growth.

Pre-eclampsia becomes eclampsia when the mother develops seizures. In the UK over the last century, the rates of eclampsia appear to have fallen. Maternal deaths due to pre-eclampsia have also fallen, although hypertension in pregnancy remains one of the leading causes of maternal death in the UK. Effective and safe control of severe hypertension in pregnancy is an important aspect of critical care management.

An enquiry into maternal deaths found that the main failings in managing pre-eclampsia were lack of routine observations of blood pressure and failure to treat significantly elevated levels of blood pressure. There were a number of women with severe hypertension in pregnancy for whom junior obstetricians had failed to consult with senior staff, and there were delays in involving anaesthetic or critical care services sufficiently early.

Women with pre-existing hypertension, diabetes, chronic kidney disease or autoimmune disease, and women who had hypertension in a previous pregnancy, are at high risk of hypertension in their current pregnancy.

## How this quality standard supports delivery of outcome frameworks

NICE quality standards describe high-priority areas for quality improvement in a defined care or service area. Each standard consists of a prioritised set of specific, concise and measurable statements. They draw on existing guidance, which provides an underpinning, comprehensive set of recommendations, and are designed to support the measurement of improvement. This quality standard, in conjunction with the guidance on which it is based, should contribute to the improvements outlined in the following 2 outcomes frameworks published by the Department of Health:

- [NHS Outcomes Framework 2013/14](#)
- [Improving outcomes and supporting transparency: a public health outcomes framework for England 2013–2016, Part 1 and Part 1A.](#)

Tables 1–2 show the outcomes, overarching indicators and improvement areas from the frameworks that the quality standard could contribute to achieving.

### Table 1 [NHS Outcomes Framework 2013/14](#)

Domain	Overarching indicators and improvement areas
--------	--

<p>1 Preventing people from dying prematurely</p>	<p><b>Overarching indicator</b></p> <p>1a Potential years of life lost (PYLL) from causes considered amenable to healthcare</p> <p><b>Improvement areas</b></p> <p>Reducing premature mortality from the major causes of death</p> <p>1.1 Under-75 mortality rate from cardiovascular disease*</p> <p>Reducing deaths in babies and young children</p> <p>1.6i Infant mortality*</p> <p>1.6ii Neonatal mortality and stillbirths</p>
<p>3 Helping people to recover from episodes of ill health or following injury</p>	<p><b>Overarching indicator</b></p> <p>3a Emergency admissions for acute conditions that should not usually require hospital admission</p>
<p>4 Ensuring that people have a positive experience of care</p>	<p><b>Overarching indicator</b></p> <p>4a.i Patient experience of GP services</p> <p>4c Friends and family test (placeholder)</p> <p><b>Improvement area</b></p> <p>Improving women and their families' experience of maternity services</p> <p>4.5 Women's experience of maternity services</p>

<p>5 Treating and caring for people in a safe environment and protecting them from avoidable harm</p>	<p><b>Overarching indicators</b></p> <p>5a Patient safety incidents reported.</p> <p>5b Safety incidents involving severe harm or death.</p> <p><b>Improvement areas</b></p> <p>Reducing the incidence of avoidable harm</p> <p>5.4 Incidence of medication errors causing serious harm</p> <p>Improving the safety of maternity services</p> <p>5.5 Admission of full-term babies to neonatal care</p>
<p><b>Alignment across the health and social care system</b></p> <p>* Indicator shared with Public Health Outcomes Framework (PHOF)</p>	

**Table 2 Public health outcomes framework for England, 2013-2016**

Domain	Objectives and indicators
<p>2 Health improvement</p>	<p><b>Objective</b></p> <p>People are helped to live healthy lifestyles, make healthy choices and reduce health inequalities</p> <p><b>Indicator</b></p> <p>2.1 Low birth weight of term babies</p>
<p>4 Healthcare public health and preventing premature mortality</p>	<p><b>Objective</b></p> <p>Reduced numbers of people living with preventable ill health and people dying prematurely, while reducing the gap between communities</p> <p><b>Indicators</b></p> <p>4.1 Infant mortality*</p> <p>4.3 Mortality from causes considered preventable**</p> <p>4.4 Mortality from all cardiovascular diseases (including heart disease and stroke)</p>



### Alignment across the health and social care system

\* Indicator shared with NHS Outcomes Framework

\*\* Indicator complementary with NHS Outcomes Framework

## Coordinated services

The quality standard for hypertension in pregnancy specifies that services should be commissioned from and coordinated across all relevant agencies encompassing the whole hypertension in pregnancy care pathway. A person-centred, integrated approach to providing services is fundamental to delivering high-quality care to women with hypertension in pregnancy.

The Health and Social Care Act 2012 sets out a clear expectation that the care system should consider NICE quality standards in planning and delivering services, as part of a general duty to secure continuous improvement in quality. Commissioners and providers of health and social care should refer to the library of NICE quality standards when designing high-quality services. Other quality standards that should also be considered when choosing, commissioning or providing a high-quality hypertension in pregnancy service are listed in [related quality standards](#).

## Training and competencies

The quality standard should be read in the context of national and local guidelines on training and competencies. All healthcare practitioners involved in assessing, caring for and treating women at risk of or with hypertension in pregnancy should have sufficient and appropriate training and competencies to deliver the actions and interventions described in the quality standard.

## List of quality statements

Quality statement 2 updates and replaces [quality statement 7: risk assessment – pre-eclampsia](#) in NICE's quality standard on [antenatal care](#).

Statement 1 Women of childbearing potential with treated hypertension are given information annually about safe antihypertensive treatment during pregnancy.

Statement 2 Pregnant women at increased risk of pre-eclampsia at the booking appointment are offered a prescription of 75–150 mg of aspirin<sup>[1]</sup> to take daily from 12 weeks until birth.

Statement 3 Pregnant women taking antihypertensive medication have a blood pressure target of 135/85 mmHg or less.

Statement 4 Pregnant women with severe hypertension are admitted for a full assessment, carried out by a healthcare professional trained in managing hypertension in pregnancy.

Statement 5 Women with pre-eclampsia who have severe hypertension or are at a high risk of adverse events, or if there are any clinical concerns are admitted to hospital and monitored.

Statement 6 Women with pre-eclampsia have a senior obstetrician involved in any decisions about the timing of birth.

Statement 7 Women who have had hypertension in pregnancy have a plan for ongoing antihypertensive management included in their postnatal care plan, which is communicated to their GP when they are transferred to community care after the birth.

Statement 8 Women who have had gestational hypertension or pre-eclampsia discuss future pregnancy and lifetime cardiovascular risks during a medical review at their 6–8 week postnatal medical check.

---

<sup>[1]</sup> Although this use is common in UK clinical practice, at the time of publication (July 2019), aspirin did not have a UK marketing authorisation for this indication. Community pharmacies cannot legally sell aspirin as a pharmacy medicine for prevention of pre-eclampsia in pregnancy in England.

Aspirin for this indication must be prescribed. The prescriber should see the summary of product characteristics for the manufacturer's advice on use in pregnancy. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's [Prescribing guidance: prescribing unlicensed medicines](#) for further information.

# Quality statement 1: Pre-pregnancy advice for women with treated hypertension

## Quality statement

Women of childbearing potential with treated hypertension are given information annually about safe antihypertensive treatment during pregnancy.

## Rationale

Information can be provided to women who may become pregnant about safe antihypertensive treatment during pregnancy as part of an annual review of hypertension care. Women should be informed about potential risks, including the risk of congenital abnormalities, linked to particular antihypertensive drugs. This should enable women to arrange a discussion with the healthcare professional responsible for managing their hypertension about alternative antihypertensive treatments if they are planning pregnancy or become pregnant.

## Quality measures

### Structure

Evidence of local arrangements to ensure that women of childbearing potential with treated hypertension are given information annually about safe antihypertensive treatment during pregnancy.

*Data source:* Local data collection.

### Process

Proportion of women who have had treated hypertension for 12 months or longer who received information about safe antihypertensive treatment during pregnancy in the past 12 months.

Numerator – the number of women in the denominator who received information about safe antihypertensive treatment during pregnancy in the past 12 months.

Denominator – the number of women of childbearing potential who have had treated hypertension

for 12 months or longer.

*Data source:* Local data collection.

## What the quality statement means for different audiences

**Service providers** ensure that systems are in place to give women of childbearing potential with treated hypertension information annually about safe antihypertensive treatment in pregnancy.

**Healthcare practitioners** give information annually to women of childbearing potential with treated hypertension about safe antihypertensive treatment in pregnancy.

**Commissioners** ensure they commission services that give information annually to women of childbearing potential with treated hypertension about safe antihypertensive treatment in pregnancy.

**Women who are having treatment for hypertension (high blood pressure) and who may become pregnant** are given information annually about safe treatment for high blood pressure during pregnancy.

## Source guidance

Hypertension in pregnancy: diagnosis and management (2019) NICE guideline NG133, recommendations 1.3.2, 1.3.4 and 1.3.5

## Definitions of terms used in this quality statement

### Safe antihypertensive treatment

Women taking angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers<sup>[2]</sup> (ARBs) should be provided with information to advise that there is an increased risk of congenital abnormalities if these drugs are taken during pregnancy, and discuss alternative antihypertensive treatment with the healthcare professional responsible for managing their hypertension, if they are planning pregnancy. If ACE inhibitors or ARBs are being taken for other conditions such as renal disease, alternative treatment should be discussed with the healthcare professional responsible for managing their condition.

Women taking thiazide or thiazide-like diuretics should be provided with information to advise that: there may be an increased risk of congenital abnormality and neonatal complications if these drugs are taken during pregnancy, and to discuss alternative antihypertensive treatment with the healthcare professional responsible for managing their hypertension, if they are planning pregnancy.

Women who take antihypertensive treatments other than ACE inhibitors, ARBs or thiazide or thiazide-like diuretics should be provided with information to advise that the limited evidence available has not shown an increased risk of congenital malformation with such treatments.

[NICE's guideline on [hypertension in pregnancy](#), recommendations 1.3.2 to 1.3.5]

## Treated hypertension

Hypertension that is treated with 1 or more antihypertensive drug.

[Adapted from NICE's [full guideline](#) on hypertension in pregnancy]

## Annual review

Women with childbearing potential are given information annually about safe antihypertensive treatment during pregnancy.

[Timeframe from expert consensus]

## Equality and diversity considerations

'Childbearing potential' should be determined for women on an individual basis. Access to information about safe antihypertensive treatment during pregnancy should not be determined solely by age, because childbearing potential is also dependent on factors other than age.

Where information is provided, there must be equal access to information for all women, including those with additional needs, such as physical or learning disabilities, and those who do not speak or read English. Women receiving information should have access to an interpreter or advocate if needed.

---

<sup>[2]</sup> In 2014, the Medicines and Healthcare products Regulatory Agency (MHRA) issued a drug safety update on [ACE inhibitors and angiotensin II receptor antagonists: not for use in pregnancy](#), which

states 'Use in women who are planning pregnancy should be avoided unless absolutely necessary, in which case the potential risks and benefits should be discussed'.

## Quality statement 2: Antenatal assessment of pre-eclampsia risk

This quality statement updates and replaces [quality statement 7: risk assessment – pre-eclampsia](#) in NICE's quality standard on [antenatal care](#).

### Quality statement

Pregnant women at increased risk of pre-eclampsia at the booking appointment are offered a prescription of 75–150 mg of aspirin<sup>[3]</sup> to take daily from 12 weeks until birth.

### Rationale

Aspirin prophylaxis, unless contraindicated, reduces the occurrence of pre-eclampsia, preterm birth and fetal and neonatal mortality in women at increased risk of developing the condition (if they have 1 high risk factor or more than 1 moderate risk factor for pre-eclampsia).

### Quality measures

#### Structure

a) Evidence of local arrangements to ensure that pregnant women have their risk factors for pre-eclampsia identified and recorded at the booking appointment.

*Data source:* Local data collection.

b) Evidence of local arrangements to ensure that pregnant women at increased risk of pre-eclampsia at the booking appointment are offered a prescription of 75–150 mg of aspirin (unless contraindicated) to take daily from 12 weeks until birth.

*Data source:* Local data collection.

#### Process

a) Proportion of pregnant women who have their risk factors for pre-eclampsia identified and recorded at the booking appointment.



Numerator – the number of women in the denominator whose risk factors for pre-eclampsia are identified and recorded.

Denominator – the number of pregnant women attending a booking appointment.

**Data source:** The [Maternity Services Data Set](#) collects data on the following risk factors at booking: hypertension, renal disease, diabetes, autoimmune disease and obstetric diagnoses from previous pregnancies including 'severe pre-eclampsia requiring preterm birth', 'eclampsia' and 'gestational hypertension'.

b) Proportion of pregnant women at increased risk of pre-eclampsia at the booking appointment who are offered a prescription of 75–150 mg of aspirin (unless contraindicated) to take daily from 12 weeks until birth.

Numerator – the number of women in the denominator offered a prescription of 75–150 mg of aspirin to take daily from 12 weeks until birth.

Denominator – the number of pregnant women at increased risk of pre-eclampsia and without contraindications to aspirin at the booking appointment.

**Data source:** Local data collection.

## Outcome

Incidence of pre-eclampsia in women at increased risk of developing pre-eclampsia.

**Data source:** The [Maternity Services Data Set](#) collects data on obstetric conditions diagnosed in the current pregnancy, including severe pre-eclampsia, severe pre-eclampsia requiring preterm birth and eclampsia.

## What the quality statement means for different audiences

**Service providers** ensure that systems are in place to offer pregnant women at increased risk of pre-eclampsia at the booking appointment a prescription of 75–150 mg of aspirin (unless contraindicated) to take daily from 12 weeks until birth.

**Healthcare practitioners** offer pregnant women at increased risk of pre-eclampsia at the booking

appointment a prescription of 75–150 mg of aspirin (unless contraindicated) to take daily from 12 weeks until birth.

Commissioners ensure they commission services that offer pregnant women at increased risk of pre-eclampsia at the booking appointment a prescription of 75–150 mg of aspirin (unless contraindicated) to take daily from 12 weeks until birth.

Pregnant women who have a higher risk of developing pre-eclampsia (a pregnancy-related rise in blood pressure with protein in the urine that happens in some pregnancies) are offered a prescription of aspirin (unless this is unsuitable) to take every day from 12 weeks of pregnancy until their baby is born.

## Source guidance

- [Antenatal care for uncomplicated pregnancies](#) (2008) NICE guideline CG62, recommendation 1.9.2.2
- [Hypertension in pregnancy: diagnosis and management](#) (2019) NICE guideline NG133, recommendations 1.1.2 and 1.1.3

## Definitions of terms used in this quality statement

### Booking appointment

The appointment where the woman enters the maternity care pathway.

[NICE's guideline on [antenatal care for uncomplicated pregnancies](#), appendix D]

### Increased risk of pre-eclampsia

Women are at an increased risk of pre-eclampsia if they have 1 high risk factor or more than 1 moderate risk factor for pre-eclampsia.

High risk factors include:

- hypertensive disease in a previous pregnancy
- chronic kidney disease
- autoimmune disease, such as systemic lupus erythematosus or antiphospholipid syndrome

- type 1 or type 2 diabetes
- chronic hypertension.

Moderate risk factors include:

- first pregnancy
- age 40 years or older
- pregnancy interval of more than 10 years
- body mass index (BMI) of 35 kg/m<sup>2</sup> or more at first visit
- family history of pre-eclampsia
- multi-fetal pregnancy.

[NICE's [full guideline](#) on hypertension in pregnancy]

## Pre-eclampsia

New hypertension (over 140 mmHg systolic or over 90 mmHg diastolic) presenting after 20 weeks of pregnancy and the coexistence of 1 or more of the following new-onset conditions:

- proteinuria (urine protein:creatinine ratio 30 mg/mmol or more, or albumin:creatinine ratio of 8 mg/mmol or more, or at least 1 g/litre [2+] on dipstick testing) or
- other maternal organ dysfunction:
  - renal insufficiency (creatinine 90 micromol/litre or more, 1.02 mg/100ml or more)
  - liver involvement (elevated transaminases [alanine aminotransferase or aspartate aminotransferase over 40 IU/litre] with or without right upper quadrant or epigastric abdominal pain)
  - neurological complications such as eclampsia, altered mental status, blindness, stroke, clonus, severe headaches or persistent visual scotomata
  - haematological complications such as thrombocytopenia (platelet count below 150,000/microlitre), disseminated intravascular coagulation or haemolysis

- uteroplacental dysfunction such as fetal growth restriction, abnormal umbilical artery Doppler waveform analysis, or stillbirth.

[NICE's guideline on hypertension in pregnancy, [terms used in this guideline](#)]

---

<sup>[3]</sup> Although this use is common in UK clinical practice, at the time of publication (July 2019), aspirin did not have a UK marketing authorisation for this indication. Community pharmacies cannot legally sell aspirin as a pharmacy medicine for prevention of pre-eclampsia in pregnancy in England. Aspirin for this indication must be prescribed. The prescriber should see the summary of product characteristics for the manufacturer's advice on use in pregnancy. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's [Prescribing guidance: prescribing unlicensed medicines](#) for further information.

## Quality statement 3: Antenatal blood pressure targets

### Quality statement

Pregnant women taking antihypertensive medication have a blood pressure target of 135/85 mmHg or less.

### Rationale

Antihypertensive treatment should aim to lower blood pressure from the moderate or severe range, while avoiding excessive reductions that may affect fetal growth.

### Quality measures

#### Structure

Evidence of local arrangements to ensure that pregnant women taking antihypertensive medication have a blood pressure target of 135/85 mmHg or less.

*Data source:* Local data collection.

#### Outcome

Rate of pregnant women with hypertension who maintain their target blood pressure throughout their pregnancy.

*Data source:* Local data collection.

### What the quality statement means for different audiences

**Service providers** ensure that there are local arrangements to set target blood pressure for pregnant women taking antihypertensive medication to 135/85 mmHg or less, and to maintain this blood pressure throughout their pregnancy.

**Healthcare practitioners** set target blood pressure for pregnant women taking antihypertensive medication to 135/85 mmHg or less, and ensure that this blood pressure is maintained throughout pregnancy.

**Commissioners** ensure they commission services that set target blood pressure for pregnant women taking antihypertensive medication to 135/85 mmHg or less, and ensure that this blood pressure is maintained throughout pregnancy.

**Pregnant women taking medication for hypertension (high blood pressure)** have a blood pressure target of 135/85 mmHg or less.

## Source guidance

[Hypertension in pregnancy: diagnosis and management](#) (2019) NICE guideline NG133, recommendations 1.3.7–1.3.9, 1.4.3 and 1.5.5

# Quality statement 4: Assessing women with severe hypertension in pregnancy

## Quality statement

Pregnant women with severe hypertension are admitted for a full assessment, carried out by a healthcare professional trained in managing hypertension in pregnancy.

## Rationale

Effective and safe control of severe hypertension is the most important aspect of critical care management, because the main causes of maternal death and severe maternal morbidity (including stroke) are the consequence of poorly controlled hypertension. Women with severe hypertension in pregnancy should be referred from primary care or emergency departments as soon as possible to receive assessment from healthcare professionals with expertise in managing hypertensive disorders. This is essential to ensure early identification of pre-eclampsia and the provision of critical care where it is needed.

## Quality measures

### Structure

Evidence of local arrangements for pregnant women with severe hypertension to be admitted for a full assessment, carried out by a healthcare professional trained in managing hypertensive disorders in pregnancy.

*Data source:* Local data collection.

### Process

Proportion of women with severe hypertension who are admitted for a full assessment, carried out by a healthcare professional trained in managing hypertensive disorders in pregnancy.

Numerator – the number of women in the denominator who are admitted for a full assessment, carried out by a healthcare professional trained in managing hypertensive disorders in pregnancy.

Denominator – the number of pregnant women with severe hypertension.

*Data source:* Local data collection.

## Outcome

Number of women with severe hypertension in pregnancy who have a stroke.

*Data source:* Local data collection.

## What the quality statement means for different audiences

**Service providers** ensure that there are local arrangements for pregnant women with severe hypertension to be admitted for a full assessment, carried out by a healthcare professional trained in managing hypertensive disorders in pregnancy.

**Healthcare practitioners** admit pregnant women with severe hypertension for a full assessment, carried out by a healthcare professional trained in managing hypertensive disorders in pregnancy.

**Commissioners** ensure they commission services that admit pregnant women with severe hypertension for a full assessment, carried out by a healthcare professional trained in managing hypertensive disorders in pregnancy.

**Pregnant women with severe hypertension (high blood pressure)** are admitted to hospital for a full assessment, carried out by a healthcare professional trained in managing high blood pressure and related conditions in pregnancy.

## Source guidance

[Hypertension in pregnancy: diagnosis and management](#) (2019) NICE guideline NG133, recommendations 1.4.1 and 1.4.3

## Definitions of terms used in this quality statement

### Full assessment

This should include blood pressure measurements, proteinuria testing and blood tests in



accordance with those set out for severe gestational hypertension and pre-eclampsia with severe hypertension in the NICE guideline on hypertension in pregnancy.

[NICE's guideline on [hypertension in pregnancy](#), recommendation 1.4.3, table 1]

## Hypertension in pregnancy

This definition includes chronic hypertension (present at the booking visit or before 20 weeks of pregnancy; this could include pre-existing hypertension), gestational hypertension (new hypertension presenting after 20 weeks without proteinuria) and pre-eclampsia (new hypertension presenting after 20 weeks of pregnancy and the coexistence of 1 or more of the following new-onset conditions:

- proteinuria (urine protein:creatinine ratio 30 mg/mmol or more, or albumin:creatinine ratio of 8 mg/mmol or more, or at least 1 g/litre [2+] on dipstick testing) or
- other maternal organ dysfunction:
  - renal insufficiency (creatinine 90 micromol/litre or more, 1.02 mg/100ml or more)
  - liver involvement (elevated transaminases [alanine aminotransferase or aspartate aminotransferase over 40 IU/litre] with or without right upper quadrant or epigastric abdominal pain)
  - neurological complications such as eclampsia, altered mental status, blindness, stroke, clonus, severe headaches or persistent visual scotomata
  - haematological complications such as thrombocytopenia (platelet count below 150,000/microlitre), disseminated intravascular coagulation or haemolysis
- uteroplacental dysfunction such as fetal growth restriction, abnormal umbilical artery Doppler waveform analysis, or stillbirth.

[NICE's guideline on hypertension in pregnancy, [terms used in this guideline](#)]

## Severe hypertension

Blood pressure over 160 mmHg systolic, or over 110 mmHg diastolic.

[NICE's guideline on hypertension in pregnancy, [terms used in this guideline](#)]

# Quality statement 5: Admission to hospital for women with pre-eclampsia

## Quality statement

Women with pre-eclampsia who have severe hypertension or are at a high risk of adverse events, or if there are any clinical concerns, are admitted to hospital and monitored.

## Rationale

Women with pre-eclampsia who have severe hypertension or are at a high risk of adverse events, or if there are any clinical concerns for the wellbeing of the woman or baby, should be admitted to hospital to enable their condition to be fully assessed and its progress monitored. High-quality care should include an integrated package of care for these women that includes admission and monitoring. Some women may need to stay in hospital until after the birth of their baby. For other women, monitoring may be possible if pre-eclampsia is stable and if the woman has access to monitoring services, and can be readmitted to hospital if her clinical condition deteriorates.

## Quality measures

### Structure

a) Evidence of local arrangements to ensure that women with pre-eclampsia who have severe hypertension or are at a high risk of adverse events, or if there are any clinical concerns, are admitted to hospital.

*Data source:* Local data collection.

b) Evidence of local arrangements for women with pre-eclampsia who have severe hypertension or are at a high risk of adverse events or if there are any clinical concerns, to receive an integrated package of care that includes monitoring of their condition.

*Data source:* Local data collection.

## Process

The proportion of women with pre-eclampsia who have severe hypertension or are at a high risk of adverse events, or if there are any clinical concerns, who are admitted to hospital and monitored.

**Numerator** – the number of women in the denominator who are admitted to hospital and monitored.

**Denominator** – the number of women with pre-eclampsia who have severe hypertension or are at a high risk of adverse events, or if there are any clinical concerns.

*Data source:* Local data collection.

## What the quality statement means for different audiences

**Service providers** ensure that local arrangements are in place for women with pre-eclampsia who have severe hypertension or are at a high risk of adverse events, or if there are any clinical concerns for the wellbeing of the woman or baby, to be admitted to hospital and for their condition to be monitored.

**Healthcare practitioners** admit women with pre-eclampsia who have severe hypertension or are at a high risk of adverse events, or if they have any clinical concerns for the wellbeing of the woman or baby, to hospital and monitor their condition.

**Commissioners** ensure they commission services that admit women with pre-eclampsia who have severe hypertension or are at a high risk of adverse events, or if there are any clinical concerns for the wellbeing of the woman or baby, to hospital and monitor their condition.

**Women with pre-eclampsia** (a pregnancy-related rise in blood pressure with protein in the urine that happens in some pregnancies) are admitted to hospital if they have very high blood pressure or a high risk of complications, or if their healthcare professional has concerns about the wellbeing of the mother or baby. The women have their condition monitored while in hospital and in the community if they go home before their baby is born.

## Source guidance

[Hypertension in pregnancy: diagnosis and management \(2019\) NICE guideline NG133,](#)

recommendations 1.5.2 and 1.5.5

## Definitions of terms used in this quality statement

### Pre-eclampsia

New hypertension (over 140 mmHg systolic or over 90 mmHg diastolic) presenting after 20 weeks of pregnancy and the coexistence of 1 or more of the following new-onset conditions:

- Proteinuria (urine protein:creatinine ratio of 30 mg/mmol or more, or albumin:creatinine ratio of 8 mg/mmol or more, or at least 1 g/litre [2+] on dipstick testing) or
- other maternal organ dysfunction:
  - renal insufficiency (creatinine 90 micromol/litre or more, 1.02 mg/100ml or more)
  - liver involvement (elevated transaminases [alanine aminotransferase or aspartate aminotransferase over 40 IU/litre] with or without right upper quadrant or epigastric abdominal pain)
  - neurological complications such as eclampsia, altered mental status, blindness, stroke, clonus, severe headaches or persistent visual scotomata
  - haematological complications such as thrombocytopenia (platelet count below 150,000/microlitre), disseminated intravascular coagulation or haemolysis
- uteroplacental dysfunction such as fetal growth restriction, abnormal umbilical artery Doppler waveform analysis, or stillbirth.

[NICE's guideline on hypertension in pregnancy, [terms used in this guideline](#)]

### Severe hypertension

Blood pressure over 160 mmHg systolic or over 110 mmHg diastolic,

[NICE's guideline on hypertension in pregnancy, [terms used in this guideline](#)]

### High risk of adverse events

High risk of adverse events suggested by the fullPIERS or PREP-S risk prediction models.

[NICE's guideline on [hypertension in pregnancy](#), recommendation 1.5.5, table 2]

## Clinical concerns

Concerns for the wellbeing of the woman or baby that could include any of the following:

- sustained systolic blood pressure of 160 mmHg or higher
- any maternal biochemical or haematological investigations that cause concern, for example, a new and persistent:
  - rise in creatinine (90 micromol/litre or more, 1 mg/100 ml or more) or
  - rise in alanine transaminase (over 70 IU/litre, or twice upper limit of normal range) or
  - fall in platelet count (under 150,000/microlitre)
- signs of impending eclampsia
- signs of impending pulmonary oedema
- other signs of severe pre-eclampsia
- suspected fetal compromise
- any other clinical signs that cause concern.

[NICE's guideline on [hypertension in pregnancy](#), recommendation 1.5.2]

## Admitted to hospital and monitored

Monitoring should include blood pressure measurements, proteinuria testing, blood tests and fetal assessments in accordance with those set out in the NICE guideline on hypertension in pregnancy.

[NICE's guideline on [hypertension in pregnancy](#), recommendation 1.5.5, table 2]

# Quality statement 6: Timing of birth for women with pre-eclampsia

## Quality statement

Women with pre-eclampsia have a senior obstetrician involved in any decisions about the timing of birth.

## Rationale

Some women who have pre-eclampsia with mild or moderate hypertension will progress to severe pre-eclampsia, which is associated with serious adverse outcomes. Because the progress of the condition differs between women, a senior obstetrician should be involved in any decisions about the timing of birth.

## Quality measures

### Structure

Evidence of local arrangements to ensure that women with pre-eclampsia have a senior obstetrician involved in decisions about the timing of birth.

*Data source:* Local data collection.

### Process

Proportion of women with pre-eclampsia who have given birth who had a senior obstetrician involved in decisions about the timing of birth.

Numerator – the number of women in the denominator who had a senior obstetrician involved in decisions about the timing of birth.

Denominator – the number of women who have given birth who had pre-eclampsia.

*Data source:* Local data collection, for example, an audit of patient maternity notes.

## Outcome

a) Number of maternal deaths of women with pre-eclampsia.

*Data source:* Local data collection.

b) Number of fetal deaths for women with pre-eclampsia.

*Data source:* Local data collection.

c) Number of admissions of women with pre-eclampsia to intensive care units (ICU).

*Data source:* Local data collection.

d) Number of admissions of babies born to women with pre-eclampsia to neonatal intensive care units (NICU).

*Data source:* Local data collection.

## What the quality statement means for different audiences

**Service providers** ensure that there are local arrangements in place for women with pre-eclampsia to have a senior obstetrician involved in decisions about the timing of birth.

**Healthcare practitioners** ensure that women with pre-eclampsia have a senior obstetrician involved in decisions about the timing of birth.

**Commissioners** ensure they commission services that assign a senior obstetrician to women with pre-eclampsia.

**Women with pre-eclampsia** (a pregnancy-related rise in blood pressure with protein in the urine that happens in some pregnancies) have a senior specialist (called an obstetrician) involved in decisions about the timing of birth.

## Source guidance

[Hypertension in pregnancy: diagnosis and management \(2019\) NICE guideline NG133,](#)

recommendation 1.5.8

## Definitions of terms used in this quality statement

### Pre-eclampsia

New hypertension (over 140 mmHg systolic or over 90 mmHg diastolic) presenting after 20 weeks of pregnancy and the coexistence of 1 or more of the following new-onset conditions:

- Proteinuria (urine protein:creatinine ratio of 30 mg/mmol or more, or albumin:creatinine ratio of 8 mg/mmol or more, or at least 1 g/litre [2+] on dipstick testing) or
- other maternal organ dysfunction:
  - renal insufficiency (creatinine 90 micromol/litre or more, 1.02 mg/100ml or more)
  - liver involvement (elevated transaminases [alanine aminotransferase or aspartate aminotransferase over 40 IU/litre] with or without right upper quadrant or epigastric abdominal pain)
  - neurological complications such as eclampsia, altered mental status, blindness, stroke, clonus, severe headaches or persistent visual scotomata
  - haematological complications such as thrombocytopenia (platelet count below 150,000/microlitre), disseminated intravascular coagulation or haemolysis
- uteroplacental dysfunction such as fetal growth restriction, abnormal umbilical artery Doppler waveform analysis, or stillbirth.

[NICE's guideline on hypertension in pregnancy, [terms used in this guideline](#)]

### Timing of birth

For indications for timing of birth, see NICE's guideline on [hypertension in pregnancy](#), recommendations 1.5.7 to 1.5.12.

### Severe pre-eclampsia

Pre-eclampsia with severe hypertension that does not respond to treatment or is associated with ongoing or recurrent severe headaches, visual scotomata, nausea or vomiting, epigastric pain, oliguria and severe hypertension, as well as progressive deterioration in laboratory blood tests



such as rising creatinine or liver transaminases or falling platelet count, or failure of fetal growth or abnormal Doppler findings.

[NICE's guideline on hypertension in pregnancy, [terms used in this guideline](#)]

# Quality statement 7: Transfer of information about ongoing management

## Quality statement

Women who have had hypertension in pregnancy have a plan for ongoing antihypertensive management included in their postnatal care plan, which is communicated to their GP when they are transferred to community care after the birth.

## Rationale

There are particular risks to women who have had hypertension in pregnancy (such as the risk of stroke) in the immediate postnatal period. The development of an individualised care plan for women who have had hypertension in pregnancy before they are transferred to community care should support ongoing antihypertensive management and enable risks to be monitored and addressed, including variations in blood pressure.

## Quality measures

### Structure

Evidence of local arrangements to communicate a plan for ongoing antihypertensive management for women who had hypertension in pregnancy to their GP when they are transferred to community care after the birth.

*Data source:* Local data collection.

### Process

The proportion of women with hypertension in pregnancy for whom a plan for ongoing antihypertensive management is communicated to their GP when they are transferred to community care after the birth.

Numerator – the number of women in the denominator for whom a plan for ongoing antihypertensive management is communicated to their GP when they are transferred to community care after the birth.

Denominator – the number of women who have given birth who had hypertension in pregnancy.

*Data source:* Local data collection.

## What the quality statement means for different audiences

**Service providers** ensure that local arrangements are in place to communicate a plan for ongoing antihypertensive management to GPs of women who had hypertension in pregnancy when they are transferred to community care after the birth.

**Healthcare practitioners** communicate a plan for ongoing antihypertensive management to GPs of women who had hypertension in pregnancy when they are transferred to community care after the birth.

**Commissioners** ensure they commission services that communicate a plan for ongoing antihypertensive management to GPs of women who had hypertension in pregnancy when they are transferred to community care after the birth.

**Women who had hypertension (high blood pressure) in pregnancy** have a plan for continuing management of their blood pressure, which is communicated to their GP when they go home after their baby is born.

## Source guidance

[Hypertension in pregnancy: diagnosis and management \(2019\) NICE guideline NG133, recommendations 1.3.20, 1.4.14, 1.5.20 and 1.10.2](#)

## Definitions of terms used in this quality statement

### A plan for ongoing antihypertensive management

This should include information about postpartum management, including a plan for ongoing management. A care plan should be written for women with gestational hypertension or pre-eclampsia who have given birth and are being transferred to community care that includes all of the following:

- who will provide follow-up care, including medical review if needed

- frequency of blood pressure monitoring needed
- thresholds for reducing or stopping treatment
- indications for referral to primary care for blood pressure review
- self-monitoring for symptoms.

[NICE's guideline on [hypertension in pregnancy](#), recommendation 1.5.20]

## Hypertension in pregnancy

This definition includes chronic hypertension (present at the booking visit or before 20 weeks of pregnancy; this could include pre-existing hypertension), gestational hypertension (new hypertension presenting after 20 weeks without proteinuria) and pre-eclampsia (new hypertension presenting after 20 weeks of pregnancy and the coexistence of 1 or more of the following new-onset conditions:

- proteinuria (urine protein:creatinine ratio of 30 mg/mmol or more, or albumin:creatinine ratio of 8 mg/mmol or more, or at least 1 g/litre [2+] on dipstick testing) or
- other maternal organ dysfunction:
  - renal insufficiency (creatinine 90 micromol/litre or more, 1.02 mg/100ml or more)
  - liver involvement (elevated transaminases [alanine aminotransferase or aspartate aminotransferase over 40 IU/litre] with or without right upper quadrant or epigastric abdominal pain)
  - neurological complications such as eclampsia, altered mental status, blindness, stroke, clonus, severe headaches or persistent visual scotomata
  - haematological complications such as thrombocytopenia (platelet count below 150,000/microlitre), disseminated intravascular coagulation or haemolysis
- Uteroplacental dysfunction such as fetal growth restriction, abnormal umbilical artery Doppler waveform analysis, or stillbirth.

[NICE's guideline on hypertension in pregnancy, [terms used in this guideline](#)]

# Quality statement 8: Communicating information about future risks

## Quality statement

Women who have had gestational hypertension or pre-eclampsia discuss future pregnancy and lifetime cardiovascular risks during a medical review at their 6–8 week postnatal medical check.

## Rationale

The long-term risks for women who have had hypertension in pregnancy include developing high blood pressure and an increased lifetime cardiovascular risk. Increased awareness and surveillance may lead to earlier intervention, such as antihypertensive treatment, with likely benefits for the woman. Women should be made aware of risks in future pregnancies resulting from hypertension in a previous pregnancy.

## Quality measures

### Structure

Evidence of local arrangements for all women who have had gestational hypertension or pre-eclampsia to have a discussion about future related risks during the medical review at their 6–8 week postnatal medical check.

*Data source:* Local data collection.

### Process

The proportion of women who have had gestational hypertension or pre-eclampsia who have a discussion about future related risks during the medical review at their 6–8 week postnatal medical check.

Numerator – the number of women in the denominator who have a discussion about future related risks.

Denominator – the number of women who have had gestational hypertension or pre-eclampsia

who have a medical review at their 6–8 week postnatal check.

*Data source:* Local data collection.

## What the quality statement means for different audiences

**Service providers** ensure that local arrangements are in place for all women who have had gestational hypertension or pre-eclampsia to have a discussion about future related risks during the medical review at their 6–8 week postnatal medical check.

**Healthcare practitioners** discuss future related risks with all women who have had gestational hypertension or pre-eclampsia during the medical review at their 6–8 week postnatal medical check.

**Commissioners** ensure that they commission services that discuss future related risks with all women who have had gestational hypertension or pre-eclampsia during the medical review at their 6–8 week postnatal medical check.

**Women who have had gestational hypertension (new high blood pressure starting after 20 weeks of pregnancy) or pre-eclampsia (a pregnancy-related rise in blood pressure with protein in the urine that happens in some pregnancies)** have an appointment with their GP or specialist 6 to 8 weeks after they have had their baby, at which they discuss their risk of having problems with their blood pressure or pregnancies in the future.

## Source guidance

[Hypertension in pregnancy: diagnosis and management \(2019\) NICE guideline NG133, recommendations 1.4.16, 1.5.22, 1.10.1 and 1.10.2](#)

## Definitions of terms used in this quality statement

### Future pregnancy and lifetime cardiovascular risk

Women who have had gestational hypertension or pre-eclampsia should be told that these conditions are associated with an increased risk of developing high blood pressure and its complications in later life.

Women who have had gestational hypertension should be told that the risk of developing:

- gestational hypertension in a future pregnancy is approximately 1 in 7 (between 11% and 15%)
- pre-eclampsia in a future pregnancy is approximately 1 in 14 (7%).

Women who have had pre-eclampsia should be told that the risk of developing:

- gestational hypertension in a future pregnancy is up to 1 in 8 (between 6% and 12%)
- pre-eclampsia in a future pregnancy is up to about 1 in 6 (16%)
- pre-eclampsia in a future pregnancy is about 1 in 3 (33%) if their pre-eclampsia led to birth between 28 and 34 weeks.

[NICE's guideline on [hypertension in pregnancy](#), recommendation 1.10.1 (table 5)]

## Gestational hypertension

New hypertension presenting after 20 weeks of pregnancy without significant proteinuria.

[NICE's guideline on hypertension in pregnancy, [terms used in this guideline](#)]

## Medical review

Women who have had gestational hypertension or pre-eclampsia should be offered a medical review by a GP or specialist at their postnatal check, which takes place 6–8 weeks after birth.

[NICE's guideline on [hypertension in pregnancy](#), recommendation 1.5.22]

## Pre-eclampsia

New hypertension (over 140 mmHg systolic or over 90 mmHg diastolic) presenting after 20 weeks of pregnancy and the coexistence of 1 or more of the following new-onset conditions:

- proteinuria (urine protein:creatinine ratio of 30 mg/mmol or more, or albumin:creatinine ratio of 8 mg/mmol or more, or at least 1 g/litre [2+] on dipstick testing) or

- other maternal organ dysfunction:
  - renal insufficiency (creatinine 90 micromol/litre or more, 1.02 mg/100ml or more)
  - liver involvement (elevated transaminases [alanine aminotransferase or aspartate aminotransferase over 40 IU/litre] with or without right upper quadrant or epigastric abdominal pain)
  - neurological complications such as eclampsia, altered mental status, blindness, stroke, clonus, severe headaches or persistent visual scotomata
  - haematological complications such as thrombocytopenia (platelet count below 150,000/microlitre), disseminated intravascular coagulation or haemolysis
- uteroplacental dysfunction such as fetal growth restriction, abnormal umbilical artery Doppler waveform analysis, or stillbirth.

[NICE's guideline on hypertension in pregnancy, [terms used in this guideline](#)]

## Equality and diversity considerations

Where information is provided, there must be equal access to information for all women, including those with additional needs, such as physical or learning disabilities, and those who do not speak or read English. Women receiving information should have access to an interpreter or advocate if needed.



# Using the quality standard

## Quality measures

The quality measures accompanying the quality statements aim to improve the structure, process and outcomes of care in areas identified as needing quality improvement. They are not a new set of targets or mandatory indicators for performance management.

See [how to use quality standards](#) for further information, including advice on using quality measures.

## Levels of achievement

Expected levels of achievement for quality measures are not specified. Quality standards are intended to drive up the quality of care, and so achievement levels of 100% should be aspired to (or 0% if the quality statement states that something should not be done). However, NICE recognises that this may not always be appropriate in practice, taking account of safety, choice and professional judgement, and therefore desired levels of achievement should be defined locally.

## Using other national guidance and policy documents

Other national guidance and current policy documents have been referenced during the development of this quality standard. It is important that the quality standard is considered by commissioners, providers, health and social care practitioners, patients, service users and carers alongside the documents listed in [development sources](#).

## Diversity, equality and language

During the development of this quality standard, equality issues have been considered and [equality assessments](#) are available.

Good communication between healthcare practitioners and women with or at risk of hypertension in pregnancy is essential. Treatment, care and support, and the information given about it, should be culturally appropriate. It should also be accessible to people with additional needs such as physical, sensory or learning disabilities, and to people who do not speak or read English. Women with or at risk of hypertension in pregnancy should have access to an interpreter or advocate if needed.

Commissioners and providers should aim to achieve the quality standard in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity and foster good relations. Nothing in this quality standard should be interpreted in a way that would be inconsistent with compliance with those duties.

## Development sources

### Evidence sources

The documents below contain recommendations from NICE guidance or other NICE-accredited recommendations that were used by the Topic Expert Group to develop the quality standard statements and measures.

- [Hypertension in pregnancy: diagnosis and management](#) (2019) NICE guideline NG133
- [Antenatal care for uncomplicated pregnancies](#) (2008) NICE guideline CG62

### Policy context

It is important that the quality standard is considered alongside current policy documents, including:

- Department of Health (2012) [Maternity services pathway payment system: a simple guide 2012-13](#)
- Department of Health (2010) [Maternity and early years: making a good start to family life](#)
- Department of Health (2009) [Delivering high quality midwifery care: the priorities, opportunities and challenges for midwives](#)
- Department of Health (2009) [Healthy child programme: pregnancy and the first 5 years of life](#)
- Department of Health (2007) [Maternity matters: choice, access and continuity of care in a safe service](#)

### Definitions and data sources for the quality measures

- [Postnatal care up to 8 weeks after birth](#) (2006) NICE guideline CG37
- [Maternity Services Data Set](#)

## Related NICE quality standards

- [Diabetes in pregnancy](#) (2016) NICE quality standard 109
- [Preterm labour and birth](#) (2016) NICE quality standard 135
- [Intrapartum care](#) (2015, updated 2017) NICE quality standard 105
- [Multiple pregnancy: twin and triplet pregnancies](#) (2013) NICE quality standard 46
- [Postnatal care](#) (2013, updated 2015) NICE quality standard 37
- [Hypertension in adults](#) (2013, updated 2015) NICE quality standard 28
- [Antenatal care](#) (2012, updated 2016) NICE quality standard 22
- [Patient experience in adult NHS services](#) (2012) NICE quality standard 15
- [Venous thromboembolism in adults: reducing the risk in hospital](#) (2010, updated 2018) NICE quality standard 3

# Topic Expert Group and NICE project team

## Topic Expert Group

**Dr David Williams (Chair)**

Consultant Obstetric Physician, University College London Hospital

**Ms Ann Marie Barnard**

Lay member

**Ms Chloe Bayfield**

Lay member

**Dr Anthony Emmerson**

Consultant Neonatologist, Central Manchester University Hospitals NHS Foundation Trust

**Mrs Frances Garraghan**

Lead Antimicrobial Pharmacist (secondment), Central Manchester Foundation Trust

**Dr Moira Mugglestone**

Director of Guideline Development, National Collaborating Centre for Women's and Children's Health

**Miss Lynda Mulhair**

Consultant Midwife, Guy's and St Thomas NHS Foundation Trust

**Dr Jenny Myers**

Senior Lecturer / Consultant Obstetrician, University of Manchester & Central Manchester University Hospitals Foundation Trust

**Dr Felicity Platt**

Consultant Anaesthetist, Queen Charlotte's and The Hammersmith Hospitals

**Dr Judy Shakespeare**

General Practitioner, Oxford

**Dr Jason Waugh**

Consultant Obstetrics / Lead clinician for Maternal Medicine, Newcastle Upon Tyne Hospitals NHS Foundation Trust

## **NICE project team**

**Dr Dylan Jones**

Associate Director

**Professor Tim Stokes**

Consultant Clinical Adviser

**Ms Rachel Neary**

Programme Manager

**Mr Tony Smith**

Technical Adviser

**Ms Michelle Gilberthorpe**

Lead Technical Analyst

**Ms Esther Clifford**

Project Manager

**Mr Lee Berry**

Co-ordinator

## Update information

**July 2019:** Changes have been made to align this quality standard with the NICE guideline on [hypertension in pregnancy](#). Statement 2 has been amended to reflect the recommended dose of aspirin for pregnant women at increased risk of pre-eclampsia. The blood pressure target in statement 3 was changed for pregnant women taking antihypertensive medication, in line with the updated guideline. In statement 5 the criteria for hospital admission and frequency of monitoring were changed. In statement 6 the involvement of a senior obstetrician in decisions on the timing of birth for women with pre-eclampsia was highlighted. References and links to source guidance have also been updated.

## About this quality standard

NICE quality standards describe high-priority areas for quality improvement in a defined care or service area. Each standard consists of a prioritised set of specific, concise and measurable statements. NICE quality standards draw on existing NICE or NICE-accredited guidance that provides an underpinning, comprehensive set of recommendations, and are designed to support the measurement of improvement.

The methods and processes for developing NICE quality standards are described in the [quality standards process guide](#).

This quality standard has been incorporated into the NICE pathways for [hypertension in pregnancy](#) and [antenatal care for uncomplicated pregnancies](#).

ISBN: 978-1-4731-0211-8

## Endorsing organisation

This quality standard has been endorsed by NHS England, as required by the Health and Social Care Act (2012)

## Supporting organisations

Many organisations share NICE's commitment to quality improvement using evidence-based guidance. The following supporting organisations have recognised the benefit of the quality standard in improving care for patients, carers, service users and members of the public. They have agreed to work with NICE to ensure that those commissioning or providing services are made aware of and encouraged to use the quality standard.

- [Action on Pre-eclampsia](#)
- [British Cardiovascular Society](#)
- [British Hypertension Society](#)
- [Royal College of General Practitioners \(RCGP\)](#)
- [Royal College of Midwives](#)
- [Royal College of Nursing \(RCN\)](#)
- [Royal College of Radiologists](#)